

DMD # 68163

Title Page

**Impact of Experimental Conditions on the Evaluation of Interactions between
Multidrug and Toxin Extrusion Proteins and Candidate Drugs**

Christian Lechner, Naoki Ishiguro, Ayano Fukuhara, Hidetada Shimizu, Naoko Ohtsu,
Masahito Takatani, Kotaro Nishiyama, Ikumi Washio, Norio Yamamura, Hiroyuki Kusuhara

Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Co.,
Ltd., Kobe, Japan (C.L., N.I., A.F., H.S., N.O., M.T., K.N., I.W., N.Y.); Laboratory of
Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of
Tokyo, Tokyo, Japan (H.K.)

DMD # 68163

Running Title Page

Running title:

Impact of experimental conditions on MATE assessment

Corresponding author:

Prof. Hiroyuki Kusuhara

Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The
University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

Phone: +81-3-5841-4770

Fax: +81-3-5841-4766

Email: kusuhara@mol.f.u-tokyo.ac.jp

Number of text pages: 22

Number of tables: 4

Number of figures: 5

Number of references: 33

Number of words (Abstract): 266

Number of words (Introduction): 610

Number of words (Discussion): 1690

Abbreviations:

DDI, drug-drug interaction;

E3S, estron-3-sulfate;

HEK293, human embryonic kidney 293,

DMD # 68163

MATE, multidrug and toxin extrusion;

MES, 4-morpholineethanesulfonic acid

MPP⁺, 1-methyl-4-phenylpyridinium;

NBuPy-Cl, N-butylpyridinium chloride

DMD # 68163

Abstract

Multidrug and toxin extrusion transporters (MATEs) have a determining influence on the pharmacokinetic profiles of many drugs and are involved in several clinical drug-drug interactions (DDIs). Cellular uptake assays with recombinant cells expressing human MATE1 or MATE2-K are widely used to investigate MATE-mediated transport for DDI assessment. However, experimental conditions and used test substrates vary among laboratories. We therefore initially examined the impact of three assay conditions that have been applied for MATE substrate and inhibitor profiling in the literature. One of the tested conditions resulted in significantly higher uptake rates of the three test substrates [¹⁴C]metformin, [³H]thiamine, and [³H]MPP⁺, but IC₅₀ values of four tested MATE inhibitors varied only slightly among the three conditions (<2.5-fold difference). Subsequently, we investigated the uptake characteristics of the five MATE substrates [¹⁴C]metformin, [³H]thiamine, [³H]MPP⁺, [³H]estrone-3-sulfate (E3S), and rhodamine 123 as well as the impact of the utilized test substrate on the inhibition profiles of ten MATE inhibitors at one selected assay condition. [³H]E3S showed atypical uptake characteristics compared to those observed with the other four substrates. IC₅₀ values of the tested inhibitors were in a similar range (<4-fold difference) when [¹⁴C]metformin, [³H]thiamine, [³H]MPP⁺ or [³H]E3S were used as substrates but were considerably higher with rhodamine 123 (9.8-fold and 4.1-fold differences compared to [¹⁴C]metformin with MATE1 and MATE2-K, respectively). This study demonstrated for the first time that the impact of assay conditions on IC₅₀ determination is negligible, that kinetic characteristics differ among used test substrates and that substrate-dependent inhibition exists for MATE1 and MATE2-K. This will give a valuable insight into the assessment of clinically relevant MATE-mediated DDIs *in vitro*.

DMD # 68163

Introduction

The renal tubular secretion of cationic drugs is mediated by specific sets of transporters in the basolateral and apical membranes of the proximal tubule cells. The first step of the renal secretion process is the basolateral uptake of organic cations from the circulation into the proximal tubule cells. The main responsible transporter for this process is organic cation transporter 2 (OCT2) (SLC22A2) (Inui *et al.*, 2000; Fujita *et al.*, 2006). In contrast to the comprehensive knowledge about this OCT2-mediated basolateral uptake of organic compounds, the understanding of the molecular mechanisms underlying the subsequent apical secretion into the tubular lumen and the identification of the involved transporters has only recently begun. Growing evidence was found that this process is presumably mediated by the two human MATE isoforms MATE1 (SLC47A1) and its paralog MATE2-K (SLC47A2), which are abundantly expressed in the apical membrane of proximal tubule cells and work as H⁺/organic ion antiporters, driven by an inwardly directed H⁺ gradient (Yonezawa and Inui, 2011; Motohashi and Inui, 2013). Both MATE isoforms share a partially overlapping substrate specificity and it has been shown that they transport a wide range of cationic, zwitterionic and anionic compounds *in vitro*, including several renally secreted drugs such as metformin, cimetidine and others (Masuda, 2006; Tanihara *et al.*, 2007; Chen *et al.*, 2009).

A number of subsequent *in vitro* and *in vivo* studies demonstrated the clinical importance of MATE transporters including their role as determinants of the pharmacokinetic profiles of various drugs and their direct involvement in several clinical DDIs (Tsuda *et al.*, 2009; Kusuhara *et al.*, 2011; Ito *et al.*, 2012). As a consequence, MATEs are now perceived as transporters of emerging importance by the International Transporter Consortium (Hillgren *et al.*, 2013) and regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have included MATE *in vitro* evaluation into

their guidelines for drug interaction studies (European Medicines Agency, 2012; U.S. Food and Drug Administration, 2012).

The most commonly used *in vitro* tool to investigate MATE-mediated transport activities are cell-based transport assays with recombinant epithelial cell lines expressing the human MATE1 or MATE2-K isoform. Numerous studies utilizing such cell systems have helped understanding the molecular function, driving force and substrate specificity of MATE transporters and allowed for the identification of a wide range of compounds as substrates or inhibitors of MATE1 and/or MATE2-K (Tanihara *et al.*, 2007; Tsuda *et al.*, 2007; He *et al.*, 2010). However, the applied experimental conditions such as buffer compositions and extra- and intracellular pH vary considerably among different laboratories and to the best of our knowledge, it has not yet been investigated whether these varying conditions can affect *in vitro* assay outputs. In addition, varying test substrates such as metformin, tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP⁺), or 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP⁺) are being used in different laboratories and it has been demonstrated for a number of SLC drug transporter isoforms such as OCT2 and the organic anion transporting polypeptides (OATPs) 2B1 and 1B1 that the utilized substrate can severely affect the inhibitory effects of tested compounds (Shirasaka *et al.*, 2012; Belzer *et al.*, 2013; Izumi *et al.*, 2013; Hacker *et al.*, 2015). First evidence of a suchlike substrate-dependent inhibition has also been reported for MATE1 (Martínez-Guerrero and Wright, 2013).

In order to investigate the possible effect of varying assay conditions, we initially examined the impact of three different conditions on substrate and inhibitor profiling of compounds using MATE1- and MATE2-K-expressing cells. Based on the results, a suitable condition was selected under which MATE-mediated uptake characteristics of five different

DMD # 68163

test substrates and the impact of the utilized test substrate on the inhibition profiles of ten different MATE inhibitors were investigated.

DMD # 68163

Materials and Methods

Chemicals and reagents

[³H]Thiamine (20 Ci/mmol) and [³H]1-methyl-4-phenylpyridinium ([³H]MPP⁺; 80 Ci/mmol) were purchased from American Radiolabeled Chemicals (Saint Louis, MO, USA), [³H]estrone-3-sulfate ([³H]E3S; 45 Ci/mmol) was purchased from PerkinElmer (Waltham, MA, USA) and [¹⁴C]metformin (90 mCi/mmol) was purchased from Moravek Biochemicals (Brea, CA, USA). Unlabeled thiamine, MPP⁺, E3S and rhodamine 123 were purchased from Sigma-Aldrich (St. Louis, MO, USA) and unlabeled metformin was purchased from Wako Pure Chemical Industries (Osaka, Japan). All other chemicals and reagents were of analytical grade and are commercially available.

Cell culture and transfection

Human embryonic kidney (HEK) 293 cells (Health Science Research Resources Bank, Osaka, Japan) were cultured in low glucose Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B (all from Life Technologies, Carlsbad, CA, USA) at 37°C in an atmosphere of 5% CO₂ and 95% relative humidity. For the generation of MATE1- and MATE2-K-expressing cells, parental HEK293 cells were initially seeded onto poly-D-lysine-coated 24-well plates at a density of 0.75×10^5 cells/well. On the next day, the cells were transfected with pcDNA3.1(-)/MATE1 (accession number NM_018242.2), pcDNA3.1(-)/MATE2-K (accession number AB250364.1) or control vector using FuGENE 6 transfection reagent (Promega, Madison, WI, USA) according to the manufacturer's instructions. Approximately 24 hours after transfection, the medium was changed to culture medium supplemented with 5 mM sodium butyrate and the cells were incubated for additional 24 hours to induce transporter gene expression.

Uptake experiments using transiently transfected HEK293 cells

Uptake experiments with transiently transfected HEK293 cells were conducted approximately 48 h after transfection using three different experimental conditions (conditions A-C, Table 1). For intracellular acidification used in condition A, cells were initially washed twice and pre-incubated with K⁺-based transport buffer (pH 7.4) supplemented with 20 mM NH₄Cl for 10 min at 37°C and subsequently incubated for additional 5 min with NH₄Cl-free K⁺-based transport buffer. In uptake experiments performed under condition B and C, cells were washed twice and pre-incubated with respective transport buffer (pH 7.4) for 10 min at 37°C. For the investigation of pH-dependent uptake at an extracellular pH between 6.0 and 7.0, 20 mM HEPES in the transport buffer was replaced with 20 mM MES.

Uptake assays were initiated by aspiration of the pre-incubation buffer and addition of transport buffer (pH 7.4) containing radiolabeled [¹⁴C]metformin, [³H]thiamine, [³H]MPP⁺, [³H]E3S or unlabeled rhodamine 123 and test inhibitors where applicable. Uptake was terminated at the designated incubation times by washing the cells three times with ice-cold transport buffer. To determine the uptake of radiolabeled substrates, cells were solubilized with NaOH for 1 h at 37°C followed by the addition of an equal amount of HCl to neutralize the cell lysates. Aliquots of the lysates were transferred to scintillation vials containing scintillation cocktail (Hionic Fluor; PerkinElmer Waltham, MA, USA) and radioactivity was measured in a liquid scintillation counter (TRI-CARB 3110 TR, PerkinElmer, Waltham, MA, USA). The remaining cell lysates were used to determine the protein concentration using the Lowry method with bovine serum albumin as standard.

To ensure reproducibility of the inhibition studies, more than 10% of all IC₅₀ values were re-determined in a separate experiment and the observed differences between repetitions were within a 2-fold range.

Rhodamine 123 measurement by fluorescence detection

Rhodamine 123 concentration was analyzed by transferring aliquots of the lysates to black 96-well plates (PerkinElmer, Waltham, MA, USA) and determining the fluorescence intensity (485 nm excitation, 535 nm emission) with a fluorescence plate reader (EnVision 2102, PerkinElmer, Waltham, MA, USA). The calibration curve in a range from 0.1 – 100 μ M was linear ($R^2 > 0.9994$) and 1 μ M rhodamine 123 solution was used as control. The obtained inter-assay coefficient of variation (plate-to-plate variation) from the control samples was 17% ($n = 11$).

Data analysis

Cellular uptake was normalized to the amount of radioactivity in the buffer and protein concentration in each well and was calculated as given in the following equation:

$$Uptake = \frac{C_{cell}}{C_{buffer}}$$

where *Uptake* is the mean uptake (μ l/designated time/mg protein), C_{cell} is the radioactivity associated with the cell specimens (dpm/designated time/mg protein), and C_{buffer} is the radioactivity concentration in the buffer (dpm/ μ l). For uptake experiments with rhodamine 123, mean uptake was calculated using fluorescence intensity instead of radioactivity. Transporter-mediated uptake was calculated by subtracting the uptake in empty-vector transfected cells from that in transporter expressing cells.

Kinetic parameters were obtained using the following equation:

$$v = \frac{V_{max} \times S}{K_m + S}$$

where v is the uptake rate of the substrate (pmol/min/mg protein), S is the substrate concentration in the buffer (μ M), K_m is the Michaelis-Menten constant (μ M), and V_{max} is the

DMD # 68163

maximum uptake rate (pmol/min/mg protein). Fitting was performed by the nonlinear least-squares method using the GraphPad PRISM software (Version 6.04, GraphPad Software, La Jolla, CA).

In case statistical significant inhibition was observed, we determined the half-inhibitory concentrations (IC₅₀) of test inhibitors using the GraphPad PRISM software based on the following four-parameter logistic equation:

$$CL = CL_{min} + \left(\frac{(CL_{max} - CL_{min})}{1 + 10^{((\log IC_{50} - I) \times Hill\ slope)}} \right)$$

where *CL*, represents the uptake clearance, *I* is the inhibitor concentration and *Hill slope* is the slope factor.

Statistical analysis

Statistically significant differences in this study were determined using Student's two-tailed unpaired *t*-tests. *p* < 0.05 and *p* < 0.01 were considered to be significant.

Results

Impact of different assay conditions on substrate profiling and inhibitor profiling

There are various experimental conditions available for *in vitro* MATE evaluation such as the use of an intracellular acidification technique to generate an outwardly-directed H⁺ gradient or the use of different buffer systems to change the extracellular concentration of H⁺ and other ions. Among these various experimental conditions, three conditions (A, B and C, see Table 1) were tested to check their impact on the substrate and inhibition profiles of known MATE substrates and inhibitors. In order to do this, we conducted uptake studies with three *in vitro* probe substrates ([¹⁴C]metformin, [³H]thiamine and [³H]MPP⁺) and examined the inhibitory effects of four inhibitors (pyrimethamine, quinidine, ondansetron and N-butylpyridinium chloride (NBuPy-Cl)) on the MATE1- and MATE2-K-mediated uptake of the three *in vitro* probe substrates at three different assay conditions.

Experiments conducted at condition A generally resulted in significantly higher uptake rates of all test substrates than experiments conducted at condition B and C (Fig. 1). In HEK293-MATE1 cells, the average substrate uptake after 1 min under condition A was 2.3-fold ([¹⁴C]metformin), 2.3-fold ([³H]thiamine), and 2.6-fold ([³H]MPP⁺) higher than under condition B and 2.4-fold ([¹⁴C]metformin), 2.3-fold ([³H]thiamine), and 2.7-fold ([³H]MPP⁺) higher than under condition C. Similar observations were made in HEK293-MATE2-K cells, where the average uptake after 1 min under condition A was 2.1-fold ([¹⁴C]metformin), 2.6-fold ([³H]thiamine), and 4.0-fold ([³H]MPP⁺) higher than under condition B and 2.8-fold ([¹⁴C]metformin), 3.6-fold ([³H]thiamine), and 5.9-fold ([³H]MPP⁺) higher than under condition C.

Under all three conditions, uptake of [¹⁴C]metformin, [³H]thiamine and [³H]MPP⁺ was decreased along with an increasing concentration of each of the four tested inhibitors except for NBuPy-Cl (Supplemental Fig. 1-4). As shown in Table 2 and Fig. 2, IC₅₀ values of all

DMD # 68163

inhibitors for MATE1- and MATE2-K-mediated uptake of the three *in vitro* probe substrates varied only slightly among the three conditions. In HEK293-MATE1 cells, all observed differences were within a 2.5-fold range with an average variation of 0.9-fold between condition A and condition B, 1.0-fold between condition A and condition C and 1.1-fold between condition B and condition C, respectively. The correlation coefficients were 0.979, 0.986, and 0.997. In HEK293-MATE2-K cells, the average variations were 1.1-fold between condition A and condition B, 1.3-fold between condition A and condition C and 1.3-fold between condition B and condition C and correlation coefficients of 0.996, 0.993, and 0.997, respectively.

Uptake characteristics of five substrates

MATE transporter isoforms accept a large variety of substrates from organic cations to organic anions and from compounds with low to high molecular weights. In order to know whether uptake profiles differ among MATE substrates, [¹⁴C]metformin, [³H]thiamine, [³H]MPP⁺, [³H]E3S and rhodamine 123 were nominated as test substrates based on selection criteria such as clinical relevance, frequency of use in the literature, and physicochemical properties. All substrate profiling studies using these compounds, i.e. time-, concentration-, and pH-dependent studies, were conducted at condition A which was previously selected as experimental condition for further characterization.

Uptake of all substrates into HEK293-MATE1- and HEK293-MATE2-K cells increased with time and was significantly higher than in the vector-transfected control cells (Supplemental Fig. 5). [¹⁴C]metformin, [³H]thiamine, and [³H]MPP⁺ uptake was linear over the first 2 min while uptake of [³H]E3S and rhodamine 123 was linear over the first 5 min. Based on these findings, we selected an incubation time for subsequent studies at which MATE1- and MATE2-K-mediated transport activities of each substrate were within the initial

DMD # 68163

linear phase (1 min for [¹⁴C]metformin, [³H]thiamine, and [³H]MPP⁺ and 2 min for [³H]E3S and rhodamine 123). Subsequently, transport activities in HEK293-MATE1 and HEK293-MATE2-K cells were assessed at increasing concentrations of the five test substrates in order to determine their kinetic profiles. The results are shown as Eadie-Hofstee plots in Fig. 3 and in Supplemental Fig. 6 and kinetic parameters (K_m and V_{max}) obtained from the concentration-dependency studies are given in Table 3. MATE1- and MATE2-K-mediated uptake of [¹⁴C]metformin, [³H]thiamine, [³H]MPP⁺ and rhodamine 123 was saturable while atypical kinetic characteristics were observed with [³H]E3S. K_m values of [¹⁴C]metformin, [³H]MPP⁺, and rhodamine 123 were lower in HEK293-MATE1 than in HEK293-MATE2-K cells, indicating higher affinities of all tested compounds for MATE1 than for MATE2-K. Rhodamine 123 had the lowest K_m values of all compounds in both HEK293-MATE1 ($K_m = 0.793 \mu\text{M}$) and HEK293-MATE2-K cells ($K_m = 10.2 \mu\text{M}$) while the highest K_m values were found for [¹⁴C]metformin transport ($K_m = 208 \mu\text{M}$ and $K_m = 2.28 \text{ mM}$ in HEK293-MATE1 and HEK293-MATE2-K cells, respectively).

Fig. 4 shows the results of the investigation of uptake of the test substrates at different pH conditions in a range from pH 6.0 to pH 8.0. The pH-dependent uptake of [¹⁴C]metformin, [³H]thiamine, and [³H]MPP⁺ showed a peak at an extracellular pH of 7.5 for MATE1 and increased until pH 8.0 for MATE2-K. The pH-dependent uptake properties of rhodamine 123 were comparable to those observed by the above-mentioned three substrates, although the peak of MATE1-mediated transport was observed at an extracellular pH of 7.0. In contrast to this, a distinct pH-dependency was found with [³H]E3S for MATE1 and MATE2-K, which both showed a continuous decrease of uptake activities along with an increasing extracellular pH.

Impact of the utilized test substrate on IC₅₀ determination

For the clarification of the question whether IC₅₀ determination is affected by the utilized substrate, the inhibitory effects of ten compounds (pyrimethamine, cimetidine, trimethoprim, zosuquidar, valsopodar, quinidine, ondansetron, famotidine, topotecan and NBuPy-Cl) on MATE1- and MATE2-K-mediated uptake of [¹⁴C]metformin, [³H]thiamine, [³H]MPP⁺, [³H]E3S and rhodamine 123 were examined. Uptake of all test substrates was decreased in the presence of an increasing concentration of each of the tested inhibitors except zosuquidar for which no inhibition was observed. The calculated IC₅₀ values are summarized in Table 4 and the comparisons of the calculated IC₅₀ values between [¹⁴C]metformin and the remaining four substrates [³H]thiamine, [³H]MPP⁺, [³H]E3S, and rhodamine 123 are shown in Fig. 5.

Compared to [¹⁴C]metformin, the IC₅₀ values for the uptake of [³H]thiamine, [³H]E3S and [³H]MPP⁺ were all within a 4-fold range (Fig. 5A-C). Low differences and a good correlation (correlation coefficients of 0.974 for MATE1 and 0.998 for MATE2-K) were found between [¹⁴C]metformin and [³H]thiamine. All observed differences were within a 2-fold (MATE1) and 3-fold (MATE2-K) range and the average variation was 1.2-fold and 1.7-fold, respectively. The observed differences between [³H]E3S and [¹⁴C]metformin were all within a 3-fold (MATE1 and MATE2-K) range with an average variation of 0.7-fold and 1.6-fold and correlation coefficients of 0.998 and 0.995 for MATE1 and MATE2-K, respectively. The observed differences between [³H]MPP⁺ and [¹⁴C]metformin were within a 3-fold (MATE1) and 4-fold (MATE2-K) range with an average variation of 1.7-fold and 2.6-fold and a correlation coefficient of 0.981 and 0.985, respectively. IC₅₀ values of all inhibitors against rhodamine 123 uptake were considerably higher than those against the other four test substrates (Fig. 5D). The average variation of IC₅₀ values compared to [¹⁴C]metformin was 9.8-fold for MATE1. Inhibitors showing >4-fold variation for MATE1 are trimethoprim (IC₅₀ >100 μM, >24-fold difference), quinidine (IC₅₀ >100 μM, >17-fold difference),

DMD # 68163

cimetidine ($IC_{50} = 36.8 \mu\text{M}$, 14-fold difference), ondansetron ($IC_{50} = 3.96 \mu\text{M}$, 9-fold difference), famotidine ($IC_{50} = 6.72 \mu\text{M}$, 7-fold difference), valsopodar ($IC_{50} >15 \mu\text{M}$, 6-fold difference) and topotecan ($IC_{50} = 26.9 \mu\text{M}$, 5-fold difference). The corresponding correlation coefficient for MATE1 was only 0.468. A similar observation was made for the inhibition of MATE2-K-mediated uptake with an average variation of 4.1-fold and >4-fold differences observed with famotidine ($IC_{50} = 24.1 \mu\text{M}$, 8-fold difference), ondansetron ($IC_{50} = 1.74 \mu\text{M}$, 7-fold difference), cimetidine ($IC_{50} = 30.5 \mu\text{M}$, 6-fold difference) and pyrimethamine ($IC_{50} = 0.833 \mu\text{M}$, 5-fold difference).

DMD # 68163

Discussion

IC₅₀ values of investigational drugs for drug transporters are determinant for the magnitude of DDIs at clinical settings. Thus, there are great concerns on the standardization of *in vitro* experimental conditions to determine robust and reliable IC₅₀ values in the pharmaceutical industry. The present study focused on MATE transporters, the importance of which is recently perceived by the regulatory authorities and the International Transporter Consortium. The latter has included an overview of available methodologies for the *in vitro* evaluation of MATEs in their latest white paper on emerging transporters of clinical importance (Hillgren *et al.*, 2013). However, the possibility of different results with different experimental conditions was not discussed, which is why the present study is an important contribution to future white papers.

In order to obtain higher activities in MATE uptake studies, an artificial pH gradient is often generated by using an alkaline buffer system in the extracellular compartment or by pre-acidification of the intracellular compartment using an NH₄Cl pre-pulse (Hillgren *et al.*, 2013). Currently, there is little information whether these varying experimental conditions affect the assessment of the interactions of test compounds with MATEs. We therefore compared the uptake of three typical *in vitro* probe substrates ([¹⁴C]metformin, [³H]thiamine, and [³H]MPP⁺) and the inhibitory profiles of four inhibitors with particular characteristics (pyrimethamine as potent, quinidine as moderate, ondansetron as MATE1-preferring, NBuPy-Cl as MATE2-K-preferring) at three different assay conditions.

Condition A (with NH₄Cl pre-pulse) resulted in significantly higher uptake rates of all three test compounds than conditions B and C (both without NH₄Cl pre-pulse). It was therefore assumed that the increased MATE activity was caused by the intracellular pre-acidification through the NH₄Cl pre-pulse used in condition A. In contrast, no significant difference was detected between condition B (K⁺-based buffer) and condition C (Na⁺-based

DMD # 68163

buffer), representing a depolarized or a polarized state of the cell membrane, respectively. This finding implicates that the membrane potential was not a determining factor for the MATE-mediated uptake of the tested substrates and is well in line with previous reports which have shown that a valinomycin-induced depolarization of the membrane had no effect on MATE1- and MATE2-K-mediated uptake of the prototypical MATE substrate TEA (Otsuka et al., 2005; Tsuda et al., 2009).

As shown in Fig. 2 and Table 2, only slight differences in the IC_{50} values among the three tested conditions were found for each combination of substrate and inhibitor (<2.5-fold difference). These results suggest that the selected condition does not substantially affect the IC_{50} determination of test compounds. Because DDI risks of drug candidates are directly extrapolated from the IC_{50} values, a robust and reliable IC_{50} determination is essential during drug development. From this perspective, the use of condition A is preferable as it results in higher uptake ratios, is therefore less susceptible to small changes of experimental conditions and will deliver more robust results.

It is well known that MATEs accept a large variety of substrate but by now, no study has directly compared the transport profiles of test substrates with diverse chemical and functional characteristics (such as their frequency of use, clinical relevance or physicochemical properties). Based on this, we chose five literature-reported MATE substrates with a range of different attributes and assessed their transport characteristics using the priorly selected experimental condition A. The selected compounds were MPP⁺ as prototypical, metformin as clinically relevant, thiamine as physiological, and E3S as atypical (i.e. anionic) substrate. In addition, rhodamine 123 was selected since it has a relatively high molecular weight and the ability to interact with P-gp, both unusual features among MATE substrates.

DMD # 68163

MATE1- and MATE2-K-mediated uptake of all test compounds was pH-dependent (Fig. 4). The observed pH-dependencies of [¹⁴C]metformin, [³H]thiamine, [³H]MPP⁺ and rhodamine 123 were similar to those reported previously for MPP⁺ and TEA (Tanihara *et al.*, 2007; Tsuda *et al.*, 2007; Dangprapai and Wright, 2011; Astorga *et al.*, 2012). As opposed to this, uptake of [³H]E3S continuously decreased with increased pH and showed atypical saturation kinetics in both HEK293-MATE1 and HEK293-MATE2-K cells (Fig. 3). Such pH-dependency has also been observed for norfloxacin (Ohta *et al.*, 2009) and cephalexin (Watanabe *et al.*, 2010). Since these compounds are weak acids (pK_a of 4.5 and 5.7, respectively), the extracellular pH affects the percentage of the neutral and zwitterionic forms at the examined range. However, E3S is a fairly strong acid with a pK_a value of -3 and it can be assumed that it predominantly exists in its anionic form over the complete extracellular pH range from pH 6.0 to 8.0. Consequently, the reasons for the unusual uptake characteristics of [³H]E3S remain unknown but might be a general feature of MATE-mediated transport of anionic drugs.

Recently, it was gradually recognized that substrate-dependent differences in IC₅₀ values exist in transporters such as OATP1B1, OATP2B1 and OCT2 (Shirasaka *et al.*, 2012; Belzer *et al.*, 2013; Izumi *et al.*, 2013; Hacker *et al.*, 2015) as well as in the cytochrome P450 enzyme CYP3A4 (Kenworthy *et al.*, 1999; Obach *et al.*, 2006). As for MATEs, Martínez-Guerrero and Wright (2013) could show a substrate-dependent inhibition of MATE1 with a set of ionic liquids. We therefore determined the IC₅₀ values of a set of ten selected inhibitors using the five aforementioned test substrates to further investigate the substrate-dependency of IC₅₀ values for MATE1 and MATE2-K. The inhibitors were selected based on clinical relevance (drugs with known DDI), high inhibition potency (low IC₅₀), and selectivity (for either MATE1 or MATE2-K) as reported in the literature. Additionally, three known P-gp inhibitors (zosuquidar, valsopodar and quinidine) were included to take account of the reported

DMD # 68163

overlapping substrate specificity between P-gp and MATEs (Tanihara et al., 2007). No pronounced substrate-dependency was found in IC₅₀ values among [¹⁴C]metformin, [³H]MPP⁺, [³H]thiamine, and [³H]E3S. In contrast, markedly higher values (>4-fold) were determined with rhodamine 123. These substantial substrate-dependent changes of IC₅₀ values with rhodamine 123 have to be taken into account when considering it as a potential test substrate in a fluorescent assay system. The use of rhodamine 123 as the only test substrate will likely lead to an underestimation of the DDI risks of candidate drugs, possibly resulting in severe clinical safety issues, and is therefore not advised.

When selecting an appropriate test substrate, one of the determining factors is a good transferability of the results to *in vivo* results from clinical studies. A clinically relevant MATE substrate, i.e. a therapeutic drug or a test substrate with transport characteristics similar to a typical test drug, can contribute to a good *in vitro-in vivo* correlation (IVIVC). In this regard, the clinically used antidiabetic metformin would be well-suited. Several studies have reported clinical DDIs with known MATE inhibitors (cimetidine, cephalexin or pyrimethamine) that significantly changed pharmacokinetic parameters of concomitantly administered metformin (Somogyi *et al.*, 1987; Jayasagar *et al.*, 2002; Kusuhara *et al.*, 2011). IC₅₀ determination in our study identified [¹⁴C]metformin as the most conservative test substrate for the detection of interactions with MATE2-K and, in most cases, with MATE1. [¹⁴C]metformin is hence unlikely to underestimate DDI risks and therefore rated as an appropriate substrate for MATE *in vitro* studies.

Kato et al. recently identified thiamine as an endogenous MATE substrate that could be a useful biomarker for the detection of DDIs involving MATEs (Kato et al., 2014). By monitoring the urinary excretion of thiamine in clinical studies, MATE-mediated DDIs of drug candidates could be evaluated without the need to administer exogenous probe drugs. However, this requires that the inhibition profiles of MATE inhibitors are similar when

DMD # 68163

thiamine and other typical MATE probe substrates such as MPP⁺ and metformin are used as substrates. Here, we have shown that [³H]thiamine has comparable *in vitro* substrate characteristics to [³H]MPP⁺ and that the IC₅₀ values of ten tested inhibitors are similar to those obtained with [³H]MPP⁺ and [¹⁴C]metformin. Therefore, [³H]thiamine could be a valuable probe substrate for the *in vitro* prediction of MATE-mediated DDIs, particularly if it is also used as biomarker in clinical studies. In this case, the *in vitro* data reflects an effectively used combination of test compounds during clinical phase 1 studies. MPP⁺ and E3S are commonly used as a prototypical *in vitro* test substrate for several other transporters but they have a low clinical relevance since they are either exogenous and neurotoxic (MPP⁺) or since there is no information about the possible use as biomarker for the assessment of MATE-mediated DDIs in the literature (E3S).

In conclusion, our study has investigated the impact of the experimental conditions and the choice of the test substrate on the determination of IC₅₀ values of known inhibitors against MATE1 and MATE2-K. We demonstrated that the IC₅₀ values of four selected inhibitors did not significantly change with the used assay condition and therefore conclude that all of the three tested *in vitro* assay conditions are applicable. Furthermore, we recommend to use [¹⁴C]metformin, [³H]thiamine, or [³H]MPP⁺ as test substrates based on the comparable IC₅₀ values of ten test inhibitors. Taken together, we believe that our findings will contribute to the establishment of a robust and reliable standard assay system for the *in vitro* assessment of MATE-mediated DDIs.

DMD # 68163

Authorship Contributions

Participated in research design: Lechner, Ishiguro, Fukuhara, Washio, Yamamura, and Kusuhara

Conducted experiments: Lechner, Shimizu, Ohtsu, Nishiyama, and Takatani

Performed data analysis: Lechner, Ishiguro, Fukuhara, Washio, Shimizu, Otsu, Nishiyama, Takatani, and Kusuhara

Wrote or contributed to the writing of the manuscript: Lechner, Ishiguro, and Kusuhara

DMD # 68163

References

- Astorga B, Ekins S, Morales M, and Wright SH (2012) Molecular Determinants of Ligand Selectivity for the Human Multidrug and Toxin Extruder Proteins MATE1 and MATE2-K. *J Pharmacol Exp Ther* 341:743–755.
- Belzer M, Morales M, Jagadish B, Mash EA, and Wright SH (2013) Substrate-Dependent Ligand Inhibition of the Human Organic Cation Transporter OCT2. *J Pharmacol Exp Ther* 346:300–310.
- Chen Y, Teranishi K, Li S, Yee SW, Hesselson S, Stryke D, Johns SJ, Ferrin TE, Kwok P, and Giacomini KM (2009) Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. *Pharmacogenomics J* 9:127–136.
- European Medicines Agency (2012) Guideline on the Investigation of Drug Interactions (EMA/CHMP/EWP/125211/2010), London, UK.
- Fujita T, Urban TJ, Leabman MK, Fujita K, and Giacomini KM (2006) Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. *J Pharm Sci* 95:25–36.
- Hacker K, Maas R, Kornhuber J, Fromm MF, and Zolk O (2015) Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates. *PLoS ONE*, 10(9):e0136451.
- Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, Zhang L, and International Transporter Consortium (2013) Emerging transporters of clinical importance: an update from the International Transporter Consortium. *Clin Pharmacol Ther* 94:52–63.

Inui K-I, Masuda S, and Saito H (2000) Cellular and molecular aspects of drug transport in the kidney. *Kidney Int* 58:944–958.

Ito S, Kusuhara H, Yokochi M, Toyoshima J, Inoue K, Yuasa H, and Sugiyama Y (2012) Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2 is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. *J Pharmacol Exp Ther* 340:393–403.

Izumi S, Nozaki Y, Komori T, Maeda K, Takenaka O, Kusano K, Yoshimura T, Kusuhara H, and Sugiyama Y (2013) Substrate-Dependent Inhibition of Organic Anion Transporting Polypeptide 1B1: Comparative Analysis with Prototypical Probe Substrates Estradiol-17 β -Glucuronide, Estrone-3-Sulfate, and Sulfobromophthalein. *Drug Metab Dispos* 41:1859–1866.

Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao C, and Madhusudan Rao Y (2002) Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers. *Drug Metabol Drug Interact* 19:41–48.

Kato K, Mori H, Kito T, Yokochi M, Ito S, Inoue K, Yonezawa A, Katsura T, Kumagai Y, Yuasa H, Moriyama Y, Inui K, Kusuhara H, and Sugiyama Y (2014) Investigation of Endogenous Compounds for Assessing the Drug Interactions in the Urinary Excretion Involving Multidrug and Toxin Extrusion Proteins. *Pharm Res* 31:136–147.

Kenworthy KE, Bloomer JC, Clarke SE, and Houston JB (1999) CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. *Br J Clin Pharmacol* 48:716–727.

König J, Müller F, and Fromm MF (2013) Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects. *Pharmacol Rev* 65:944–966.

DMD # 68163

Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, and Sugiyama Y (2011) Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects. *Clin Pharmacol Ther* 89:837–844.

Martínez-Guerrero LJ, and Wright SH (2013) Substrate-dependent inhibition of human MATE1 by cationic ionic liquids. *J Pharmacol Exp Ther* 346:495-503.

Matsushima S, Maeda K, Inoue K, Ohta K -y., Yuasa H, Kondo T, Nakayama H, Horita S, Kusuhara H, and Sugiyama Y (2009) The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine. *Drug Metab Dispos* 37:555–559.

Morrissey KM, Stocker SL, Wittwer MB, Xu L, and Giacomini KM (2013) Renal Transporters in Drug Development. *Annu Rev Pharmacol Toxicol* 53:503–529.

Motohashi H, and Inui K (2013) Multidrug and toxin extrusion family SLC47: Physiological, pharmacokinetic and toxicokinetic importance of MATE1 and MATE2-K. *Mol Aspects Med* 34:661–668.

Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. *J Pharmacol Exp Ther* 316:336–348.

Ohta K, Imamura Y, Okudaira N, Atsumi R, Inoue K, and Yuasa H (2009) Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. *J Pharmacol Exp Ther* 328:628–634.

DMD # 68163

Omote H, Hiasa M, Matsumoto T, Otsuka M, and Moriyama Y (2006) The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. *Trends Pharmacol Sci* 27:587–593.

Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, and Moriyama Y (2005) A human transporter protein that mediates the final excretion step for toxic organic cations. *Proc Natl Acad Sci U S A* 102:17923–17928.

Shirasaka Y, Mori T, Shichiri M, Nakanishi T, and Tamai I (2012) Functional pleiotropy of organic anion transporting polypeptide OATP2B1 due to multiple binding sites. *Drug Metab Pharmacokinet* 27:360–364.

Somogyi A, Stockley C, Keal J, Rolan P, and Bochner F (1987) Reduction of metformin renal tubular secretion by cimetidine in man. *Br J Clin Pharmacol* 23:545–551.

Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, and Inui K (2007) Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H⁺-organic cation antiporters. *Biochem Pharmacol* 74:359–371.

Tsuda M, Terada T, Asaka J, Ueba M, Katsura T, and Inui K (2007) Oppositely directed H⁺ gradient functions as a driving force of rat H⁺/organic cation antiporter MATE1. *Am J Physiol Renal Physiol* 292:F593–598.

Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T, and Inui K (2009) Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells. *J Pharmacol Exp Ther* 329:185–191.

DMD # 68163

U.S. Food and Drug Administration (2012) Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendation. Draft Guidance, Silver Spring, Maryland.

Watanabe S, Tsuda M, Terada T, Katsura T, and Inui K-I (2010) Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. *J Pharmacol Exp Ther* 334:651–656.

Yasujima T, Ohta K -y., Inoue K, Ishimaru M, and Yuasa H (2010) Evaluation of 4',6-Diamidino-2-phenylindole as a Fluorescent Probe Substrate for Rapid Assays of the Functionality of Human Multidrug and Toxin Extrusion Proteins. *Drug Metab Dispos* 38:715–721.

Yonezawa A, and Inui K (2011) Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics: Multidrug and toxin extrusion MATE/SLC47A family. *Br J Pharmacol* 164:1817–1825.

DMD # 68163

Footnotes

This study was supported by Boehringer Ingelheim.

DMD # 68163

Figure Legends

Fig 1. Uptake of [^{14}C]metformin (A), [^3H]thiamine (B), and [^3H]MPP $^+$ (C) at three different assay conditions. Uptake of [^{14}C]metformin (10 μM), [^3H]thiamine (1 μM), and [^3H]MPP $^+$ (1 μM) was determined for 1 min in HEK293-MATE1, HEK293-MATE2-K and HEK293-mock cells at three different assay conditions (conditions A-C, see Table 1). Each bar represents the mean value \pm S.E of triplicate measures from at least 4 separate experiments. Asterisks (*) represent significantly different uptake compared to condition A ($p < 0.01$).

Fig. 2. Comparison of IC_{50} values between different assay conditions. Uptake of [^{14}C]metformin (10 μM , 1 min), [^3H]thiamine (1 μM , 1 min), and [^3H]MPP $^+$ (1 μM , 1 min) was determined in the absence and presence of various concentrations of inhibitors as shown in Supplemental Fig. 1-4 and IC_{50} values were estimated by nonlinear regression analysis (see Table 2). All experiments were conducted with HEK293-MATE1 (closed squares) and HEK293-MATE2-K cells (open squares) and at three different assay conditions (condition A-C, see Table 1). (A) condition A vs. condition B, (B) condition A vs. condition C, (C) condition B vs. condition C. Each point represents the mean value \pm relative error from one experiment.

Fig. 3. Concentration-dependent uptake of [^{14}C]metformin (A), [^3H]thiamine (B), [^3H]MPP $^+$ (C), [^3H]E3S (D) and rhodamine 123 (E) by HEK293 cells expressing MATE1 or MATE2-K. Uptake of [^{14}C]metformin (10 - 10000 μM , 1 min), [^3H]thiamine (0.1 - 1000 μM , 1 min), [^3H]MPP $^+$ (0.1 - 1000 μM , 1 min), [^3H]E3S (0.1 - 300 μM , 2 min) and rhodamine 123 (0.1 - 100 μM , 2 min) was determined in HEK293-MATE1 (closed circles) and HEK293-MATE2-K (closed squares) at condition A (see Table 1). Data are shown as Eadie-Hofstee plots.

DMD # 68163

Transporter-mediated uptake was calculated by subtracting the uptake in HEK293-mock cells from that in transporter expressing cells. Each point represents the mean value \pm S.E. of triplicate measures from one experiment in case of [14 C]metformin and [3 H]MPP $^+$ and from one representative experiment out of at least two separate experiments in case of the other substrates.

Fig. 4. pH-dependent uptake of [14 C]metformin (A), [3 H]thiamine (B), [3 H]MPP $^+$ (C), [3 H]E3S (D) and rhodamine 123 (E) by HEK293 cells expressing MATE1 or MATE2-K and control cells. Uptake of [14 C]metformin (10 μ M, 1 min), [3 H]thiamine (1 μ M, 1 min), [3 H]MPP $^+$ (1 μ M, 1 min), [3 H]E3S (10 μ M, 2 min) and rhodamine 123 (1 μ M, 2 min) was determined in HEK293-MATE1 (closed circles), HEK293-MATE2-K (closed squares) and HEK293-mock cells (open circles) at condition A (see Table 1). Each point represents the mean value \pm S.E. of triplicate measures from one experiment in case of [14 C]metformin and from one representative experiment out of at least two separate experiments in case of the other substrates.

Fig. 5. Comparison of IC $_{50}$ values between different test substrates. Uptake of [14 C]metformin (10 μ M, 1 min), [3 H]thiamine (1 μ M, 1 min), [3 H]MPP $^+$ (1 μ M, 1 min), [3 H]E3S (10 μ M, 2 min) and rhodamine 123 (1 μ M, 2 min) was determined in the absence and presence of various concentrations of inhibitors and IC $_{50}$ values were estimated by nonlinear regression analysis (see Table 4). All experiments were conducted with HEK293-MATE1 (closed squares) and HEK293-MATE2-K cells (open squares) at condition A (see Table 1). (A) [14 C]metformin vs. [3 H]thiamine, (B) [14 C]metformin vs. MPP $^+$, (C) [14 C]metformin vs. [3 H]E3S, and (D) [14 C]metformin vs. Rhodamine 123. Each point represents the mean value \pm relative error from one experiment.

Tables

Table 1. Experimental conditions

Condition	pH	NH ₄ Cl pre-pulse	Transport buffer	Transport buffer composition (mM)						
				NaCl	KCl	KH ₂ PO ₄	MgSO ₄	CaCl ₂	HEPES	Glucose
A	7.4	yes	K ⁺ -based	-	130	2.0	1.2	1.0	20	5.0
B	7.4	no	K ⁺ -based	-	130	2.0	1.2	1.0	20	5.0
C	7.4	no	Na ⁺ -based	118	4.7	1.2	1.2	1.5	25	11

Table 2. IC₅₀ values for MATE1- and MATE2-K-mediated uptake of [³H]MPP⁺, [³H]thiamine and [¹⁴C]metformin at different assay conditions. Uptake of [¹⁴C]metformin (10 μM, 1 min), [³H]thiamine (1 μM, 1 min), and [³H]MPP⁺ (1 μM, 1 min) was determined in the absence and presence of various concentrations of inhibitors at three different assay conditions (condition A-C, see Table 1) as shown in Supplemental Fig. 1-4. IC₅₀ values were estimated by nonlinear regression analysis and are given as mean ± S.D. from one experiment.

Inhibitor	Condition	Substrate		
		[¹⁴ C]metformin	[³ H]thiamine	[³ H]MPP ⁺
		IC ₅₀ (μM), MATE1		
Pyrimethamine	A	0.313 ± 0.052	0.330 ± 0.052	0.492 ± 0.039
	B	0.337 ± 0.065	0.268 ± 0.020	0.353 ± 0.028
	C	0.583 ± 0.043	0.397 ± 0.072	0.443 ± 0.031
Quinidine	A	5.82 ± 0.06	6.77 ± 0.05	6.77 ± 0.08
	B	5.77 ± 0.05	5.81 ± 0.05	6.26 ± 0.04
	C	2.48 ± 0.70	3.64 ± 0.08	4.34 ± 0.07
Ondansetron	A	0.436 ± 0.083	0.493 ± 0.041	0.797 ± 0.025
	B	0.570 ± 0.040	0.344 ± 0.043	0.475 ± 0.068
	C	0.499 ± 0.040	0.430 ± 0.028	0.619 ± 0.033

DMD # 68163

NBuPy-Cl	A	55.2 ± 0.1	83.5 ± 0.1	76.8 ± 0.1
	B	69.8 ± 0.1	71.0 ± 0.1	65.8 ± 0.1
	C	74.5 ± 0.1	78.9 ± 0.1	81.1 ± 0.1
IC ₅₀ (μM), MATE2-K				
Pyrimethamine	A	0.180 ± 0.083	0.372 ± 0.068	0.650 ± 0.063
	B	0.281 ± 0.073	0.170 ± 0.053	0.615 ± 0.048
	C	0.298 ± 0.068	0.319 ± 0.113	0.703 ± 0.065
Quinidine	A	6.44 ± 0.06	11.7 ± 0.1	17.6 ± 0.1
	B	9.79 ± 0.05	11.4 ± 0.0	20.6 ± 0.1
	C	12.3 ± 0.1	13.9 ± 0.1	31.8 ± 0.1
Ondansetron	A	0.259 ± 0.086	0.597 ± 0.071	0.725 ± 0.055
	B	0.388 ± 0.042	0.251 ± 0.106	0.869 ± 0.080
	C	0.527 ± 0.064	0.438 ± 0.040	0.979 ± 0.083
NBuPy-Cl	A	>100	>100	86.5 ± 0.1
	B	>100	>100	>100
	C	>100	>100	>100

Table 3. Saturation kinetics of MATE1- and MATE2-K-mediated uptake of [¹⁴C]metformin, [³H]thiamine, [³H]MPP⁺, [³H]E3S and rhodamine 123. Uptake of [¹⁴C]metformin (10 - 10000 μM, 1 min), [³H]thiamine (0.1 - 1000 μM, 1 min), [³H]MPP⁺ (0.1 - 1000 μM, 1 min), [³H]E3S (0.1 - 300 μM, 2 min) and rhodamine 123 (0.1 - 100 μM, 2 min) was determined at condition A (see Table 1). Kinetic parameters were estimated by nonlinear regression analysis and are given as mean ± S.D from one experiment in case of [¹⁴C]metformin and [³H]MPP⁺ and from one representative experiment out of at least two separate experiments in case of the other substrates.

Substrate	K_m (μM)		V_{max} (pmol/min/mg protein)	
	MATE1	MATE2-K	MATE1	MATE2-K
[¹⁴ C]metformin	208 ± 29	2275 ± 284	8890 ± 282	13779 ± 652
[³ H]thiamine	31.0 ± 4.5	23 ± 2.4	1584 ± 63	674 ± 25
[³ H]MPP ⁺	47.6 ± 2.1	81.2 ± 7.7	5199 ± 66	4038 ± 117
[³ H]E3S ^a	n.d.	n.d.	n.d.	n.d.
Rhodamine 123	0.793 ± 0.395	10.2 ± 1.2	372 ± 41	1796 ± 64

n.d.: not determined

^aKinetic parameters of [³H]E3S were not determined due to its atypical saturation kinetics.

Table 4. IC₅₀ values for MATE1- and MATE2-K-mediated uptake of [¹⁴C]metformin, [³H]thiamine, [³H]MPP⁺, [³H]E3S and rhodamine 123. Uptake of [¹⁴C]metformin (10 μM, 1 min), [³H]thiamine (1 μM, 1 min), [³H]MPP⁺ (1 μM, 1 min), [³H]E3S (10 μM, 2 min) and rhodamine 123 (1 μM, 2 min) was determined in the absence and presence of various concentrations of inhibitors. IC₅₀ values were estimated by nonlinear regression analysis and are given as mean ± S.D. from one experiment.

Inhibitor	Category	Substrate				
		[¹⁴ C]metformin	[³ H]thiamine	[³ H]MPP ⁺	[³ H]E3S	Rhodamine 123
IC ₅₀ (μM), MATE1						
Pyrimethamine	Drug with known DDI	0.313 ± 0.052	0.330 ± 0.052	0.492 ± 0.039	0.150 ± 0.057	1.16 ± 0.13
Cimetidine	Drug with known DDI	2.56 ± 0.04	3.19 ± 0.04	4.43 ± 0.05	1.30 ± 0.06	36.8 ± 0.2
Trimethoprim	Drug with known DDI	4.13 ± 0.09	4.19 ± 0.05	8.16 ± 0.06	2.69 ± 0.03	>100
Zosuquidar	P-gp inhibitor	>50	>50	>50	>50	>50
Valspodar	P-gp inhibitor	2.67 ± 0.05	4.83 ± 0.06	5.89 ± 0.05	2.02 ± 0.07	>15
Quinidine	P-gp inhibitor	5.82 ± 0.06	6.77 ± 0.05	6.77 ± 0.08	6.96 ± 0.06	>100
Ondansetron	High inhibition potency	0.436 ± 0.083	0.493 ± 0.041	0.797 ± 0.025	0.287 ± 0.029	3.96 ± 0.07
Famotidine	Selectivity (MATE1 > MATE2-K)	0.905 ± 0.046	1.20 ± 0.03	1.67 ± 0.03	0.456 ± 0.036	6.72 ± 0.16

DMD # 68163

Topotecan	Selectivity (MATE1 > MATE2-K)	5.34 ± 0.03	4.49 ± 0.03	8.25 ± 0.05	2.66 ± 0.03	26.9 ± 0.1
NBuPy-Cl	Selectivity (MATE2-K > MATE1)	55.2 ± 0.1	83.5 ± 0.1	76.8 ± 0.1	51.8 ± 0.1	>100
IC ₅₀ (μM), MATE2-K						
Pyrimethamine	Drug with known DDI	0.180 ± 0.083	0.372 ± 0.068	0.650 ± 0.063	0.372 ± 0.112	0.833 ± 0.130
Cimetidine	Drug with known DDI	5.47 ± 0.06	11.2 ± 0.0	13.4 ± 0.1	11.2 ± 0.1	30.5 ± 0.1
Trimethoprim	Drug with known DDI	0.421 ± 0.052	0.440 ± 0.027	1.22 ± 0.03	0.440 ± 0.047	1.05 ± 0.12
Zosuquidar	P-gp inhibitor	>50	>50	>50	>50	>50
Valspodar	P-gp inhibitor	0.118 ± 0.039	0.169 ± 0.025	0.238 ± 0.034	0.109 ± 0.031	0.219 ± 0.050
Quinidine	P-gp inhibitor	6.44 ± 0.06	11.7 ± 0.1	17.6 ± 0.1	14.7 ± 0.2	28.5 ± 0.1
Ondansetron	High inhibition potency	0.259 ± 0.086	0.597 ± 0.071	0.725 ± 0.055	0.430 ± 0.086	1.74 ± 0.07
Famotidine	Selectivity (MATE1 > MATE2-K)	3.10 ± 0.09	5.30 ± 0.07	8.88 ± 0.05	6.66 ± 0.10	24.1 ± 0.1
Topotecan	Selectivity (MATE1 > MATE2-K)	5.43 ± 0.04	9.15 ± 0.04	15.8 ± 0.0	6.11 ± 0.08	14.7 ± 0.1

DMD # 68163

NBuPy-Cl	Selectivity (MATE2-K > MATE1)	>100	>100	86.5 ± 0.1	>100	>100
----------	----------------------------------	------	------	------------	------	------




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5